Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients : A Clinical Validation Trial and Implementation Study
© 2020 The Author(s)..
There is an urgent need for rapid SARS-CoV-2 testing in hospitals to limit nosocomial spread. We report an evaluation of point of care (POC) nucleic acid amplification testing (NAAT) in 149 participants with parallel combined nasal and throat swabbing for POC versus standard lab RT-PCR testing. Median time to result is 2.6 (IQR 2.3-4.8) versus 26.4 h (IQR 21.4-31.4, p < 0.001), with 32 (21.5%) positive and 117 (78.5%) negative. Cohen's κ correlation between tests is 0.96 (95% CI 0.91-1.00). When comparing nearly 1,000 tests pre- and post-implementation, the median time to definitive bed placement from admission is 23.4 (8.6-41.9) versus 17.1 h (9.0-28.8), p = 0.02. Mean length of stay on COVID-19 "holding" wards is 58.5 versus 29.9 h (p < 0.001). POC testing increases isolation room availability, avoids bed closures, allows discharge to care homes, and expedites access to hospital procedures. POC testing could mitigate the impact of COVID-19 on hospital systems.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:1 |
---|---|
Enthalten in: |
Cell reports. Medicine - 1(2020), 5 vom: 25. Aug., Seite 100062 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Collier, Dami A [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Completed 22.02.2022 Date Revised 23.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.xcrm.2020.100062 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM314117857 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM314117857 | ||
003 | DE-627 | ||
005 | 20231225152039.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.xcrm.2020.100062 |2 doi | |
028 | 5 | 2 | |a pubmed24n1047.xml |
035 | |a (DE-627)NLM314117857 | ||
035 | |a (NLM)32838340 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Collier, Dami A |e verfasserin |4 aut | |
245 | 1 | 0 | |a Point of Care Nucleic Acid Testing for SARS-CoV-2 in Hospitalized Patients |b A Clinical Validation Trial and Implementation Study |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 22.02.2022 | ||
500 | |a Date Revised 23.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Author(s). | ||
520 | |a There is an urgent need for rapid SARS-CoV-2 testing in hospitals to limit nosocomial spread. We report an evaluation of point of care (POC) nucleic acid amplification testing (NAAT) in 149 participants with parallel combined nasal and throat swabbing for POC versus standard lab RT-PCR testing. Median time to result is 2.6 (IQR 2.3-4.8) versus 26.4 h (IQR 21.4-31.4, p < 0.001), with 32 (21.5%) positive and 117 (78.5%) negative. Cohen's κ correlation between tests is 0.96 (95% CI 0.91-1.00). When comparing nearly 1,000 tests pre- and post-implementation, the median time to definitive bed placement from admission is 23.4 (8.6-41.9) versus 17.1 h (9.0-28.8), p = 0.02. Mean length of stay on COVID-19 "holding" wards is 58.5 versus 29.9 h (p < 0.001). POC testing increases isolation room availability, avoids bed closures, allows discharge to care homes, and expedites access to hospital procedures. POC testing could mitigate the impact of COVID-19 on hospital systems | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a Validation Study | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a POC | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a diagnostic test | |
650 | 4 | |a infection control | |
650 | 4 | |a nosocomial | |
650 | 4 | |a point of care | |
700 | 1 | |a Assennato, Sonny M |e verfasserin |4 aut | |
700 | 1 | |a Warne, Ben |e verfasserin |4 aut | |
700 | 1 | |a Sithole, Nyarie |e verfasserin |4 aut | |
700 | 1 | |a Sharrocks, Katherine |e verfasserin |4 aut | |
700 | 1 | |a Ritchie, Allyson |e verfasserin |4 aut | |
700 | 1 | |a Ravji, Pooja |e verfasserin |4 aut | |
700 | 1 | |a Routledge, Matthew |e verfasserin |4 aut | |
700 | 1 | |a Sparkes, Dominic |e verfasserin |4 aut | |
700 | 1 | |a Skittrall, Jordan |e verfasserin |4 aut | |
700 | 1 | |a Smielewska, Anna |e verfasserin |4 aut | |
700 | 1 | |a Ramsey, Isobel |e verfasserin |4 aut | |
700 | 1 | |a Goel, Neha |e verfasserin |4 aut | |
700 | 1 | |a Curran, Martin |e verfasserin |4 aut | |
700 | 1 | |a Enoch, David |e verfasserin |4 aut | |
700 | 1 | |a Tassell, Rhys |e verfasserin |4 aut | |
700 | 1 | |a Lineham, Michelle |e verfasserin |4 aut | |
700 | 1 | |a Vaghela, Devan |e verfasserin |4 aut | |
700 | 1 | |a Leong, Clare |e verfasserin |4 aut | |
700 | 1 | |a Mok, Hoi Ping |e verfasserin |4 aut | |
700 | 1 | |a Bradley, John |e verfasserin |4 aut | |
700 | 1 | |a Smith, Kenneth G C |e verfasserin |4 aut | |
700 | 1 | |a Mendoza, Vivienne |e verfasserin |4 aut | |
700 | 1 | |a Demiris, Nikos |e verfasserin |4 aut | |
700 | 1 | |a Besser, Martin |e verfasserin |4 aut | |
700 | 1 | |a Dougan, Gordon |e verfasserin |4 aut | |
700 | 1 | |a Lehner, Paul J |e verfasserin |4 aut | |
700 | 1 | |a Siedner, Mark J |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Hongyi |e verfasserin |4 aut | |
700 | 1 | |a Waddington, Claire S |e verfasserin |4 aut | |
700 | 1 | |a Lee, Helen |e verfasserin |4 aut | |
700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
700 | 0 | |a CITIID-NIHR COVID BioResource Collaboration |e verfasserin |4 aut | |
700 | 1 | |a Baker, Stephen |e investigator |4 oth | |
700 | 1 | |a Bradley, John |e investigator |4 oth | |
700 | 1 | |a Dougan, Gordon |e investigator |4 oth | |
700 | 1 | |a Goodfellow, Ian |e investigator |4 oth | |
700 | 1 | |a Gupta, Ravindra K |e investigator |4 oth | |
700 | 1 | |a Lehner, Paul J |e investigator |4 oth | |
700 | 1 | |a Lyons, Paul |e investigator |4 oth | |
700 | 1 | |a Matheson, Nicholas J |e investigator |4 oth | |
700 | 1 | |a Smith, Kenneth Gc |e investigator |4 oth | |
700 | 1 | |a Toshner, Mark |e investigator |4 oth | |
700 | 1 | |a Weekes, Michael P |e investigator |4 oth | |
700 | 1 | |a Brown, Nick |e investigator |4 oth | |
700 | 1 | |a Curran, Martin |e investigator |4 oth | |
700 | 1 | |a Palmar, Surendra |e investigator |4 oth | |
700 | 1 | |a Zhang, Hongyi |e investigator |4 oth | |
700 | 1 | |a Enoch, David |e investigator |4 oth | |
700 | 1 | |a Chapman, Daniel |e investigator |4 oth | |
700 | 1 | |a Shaw, Ashley |e investigator |4 oth | |
700 | 1 | |a Mendoza, Vivien |e investigator |4 oth | |
700 | 1 | |a Jose, Sherly |e investigator |4 oth | |
700 | 1 | |a Bermperi, Areti |e investigator |4 oth | |
700 | 1 | |a Zerrudo, Julie Ann |e investigator |4 oth | |
700 | 1 | |a Kourampa, Evgenia |e investigator |4 oth | |
700 | 1 | |a Saunders, Caroline |e investigator |4 oth | |
700 | 1 | |a de Jesus, Ranalie |e investigator |4 oth | |
700 | 1 | |a Domingo, Jason |e investigator |4 oth | |
700 | 1 | |a Pasquale, Ciro |e investigator |4 oth | |
700 | 1 | |a Vergese, Bensi |e investigator |4 oth | |
700 | 1 | |a Vargas, Phoebe |e investigator |4 oth | |
700 | 1 | |a Fabiculana, Marivic |e investigator |4 oth | |
700 | 1 | |a Perales, Marlyn |e investigator |4 oth | |
700 | 1 | |a Skells, Richard |e investigator |4 oth | |
700 | 1 | |a Mynott, Lee |e investigator |4 oth | |
700 | 1 | |a Blake, Elizabeth |e investigator |4 oth | |
700 | 1 | |a Bates, Amy |e investigator |4 oth | |
700 | 1 | |a Vallier, Anne-Laure |e investigator |4 oth | |
700 | 1 | |a Williams, Alexandra |e investigator |4 oth | |
700 | 1 | |a Phillips, David |e investigator |4 oth | |
700 | 1 | |a Chiu, Edmund |e investigator |4 oth | |
700 | 1 | |a Overhill, Alex |e investigator |4 oth | |
700 | 1 | |a Ramenante, Nicola |e investigator |4 oth | |
700 | 1 | |a Sipple, Jamal |e investigator |4 oth | |
700 | 1 | |a Frost, Steven |e investigator |4 oth | |
700 | 1 | |a Knock, Helena |e investigator |4 oth | |
700 | 1 | |a Hardy, Richard |e investigator |4 oth | |
700 | 1 | |a Foster, Emily |e investigator |4 oth | |
700 | 1 | |a Davidson, Fiona |e investigator |4 oth | |
700 | 1 | |a Rundell, Viona |e investigator |4 oth | |
700 | 1 | |a Bundi, Purity |e investigator |4 oth | |
700 | 1 | |a Abeseabe, Richmond |e investigator |4 oth | |
700 | 1 | |a Clark, Sarah |e investigator |4 oth | |
700 | 1 | |a Vicente, Isabel |e investigator |4 oth | |
773 | 0 | 8 | |i Enthalten in |t Cell reports. Medicine |d 2020 |g 1(2020), 5 vom: 25. Aug., Seite 100062 |w (DE-627)NLM310587662 |x 2666-3791 |7 nnns |
773 | 1 | 8 | |g volume:1 |g year:2020 |g number:5 |g day:25 |g month:08 |g pages:100062 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.xcrm.2020.100062 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 1 |j 2020 |e 5 |b 25 |c 08 |h 100062 |